ArticleClinical ophthalmology (Auckland, N.Z.)2025
Outcomes of Collagen Crosslinking in Patients with Keratoconus and Co-Existent Limbal Stem Cell Deficiency.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyse the outcomes of collagen crosslinking (CXL) in eyes with progressive keratoconus (KC) and secondary limbal stem cell deficiency (LSCD) caused by vernal keratoconjunctivitis (VKC). Methods: Patients with progressive KC and VKC having co-existent LSCD who underwent CXL from May 2016 to October 2023 were included. Demographic details, clinical and corneal topography data were collected preoperatively, at 1-months, 3-months, 6-months and 1-year. Details of the CXL procedure and early postoperative complications were noted. Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA) and topographic indices including flattest keratometry (K1), steepest keratometry (K2), mean keratometry (Km), maximum keratometry (Kmax) and thinnest corneal thickness (TCT) were noted at 1-year and compared with the preoperative data. Results: Fifteen eyes of 11 patients were included in the study. Partial LSCD was present in 14 eyes and underwent epithelium-off CXL and 1 eye with total LSCD underwent transepithelial CXL. The mean logarithm of the minimum angle of resolution (logMAR) UCVA pre-CXL was 0.67±0.38 which improved to 0.54±0.32 at 6-months (p=0.05) and 0.65±0.35 logMAR at 1-year post-CXL (p = 0.005). Pre-CXL Km was 53.5±4.77 (median-51.95D) which decreased to post-cxl value of 51.72±3.65 at 6-months (p=0.014) and 52.34±3.83 (median-51.3D) at 1-year (p=0.09). Kmax reduced from 63.41±7.11 (median-63.7D) pre-CXL to 60.65±5.31 (median-59.6) (p=0.05) at 6-months and 61.4±6.01 (median-61.9D) at 1-year post-CXL (p=0.115). Of the 14 eyes that underwent epi-off CXL, 2 eyes (14.28%) had persistent epithelial defects (PEDs), one of which needed amniotic membrane graft (AMG). Conclusion: In our series, most eyes with keratoconus having co-existent LSCD had uncomplicated ocular surface healing post-CXL and remained stable at 1-year with significant improvement in visual acuity. Our study shows that CXL can be successfully performed in cases of Keratoconus with co-existing LSCD without any serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.